louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00566111: Ceftriaxone in the Management of Bipolar Depression
Official title: Modulation of Glutamatergic Neurotransmission in the Treatment of Bipolar Depression
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Bipolar Depression
Keywords: Ceftriaxone
Acute Antidepressant Effects
Glutamatergic System
Double-Blind
Mood Disorders
Bipolar Disorder
Depression
Affective Disorders
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: Stanley Medical Research Institute
First posted: 2007-12-03
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient, placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar disorder, currently depressed, who have failed to respond to conventional treatments.


Eligibility criteria: Inclusion Criteria:

* DSM-IV diagnosis of bipolar disorder
* Presence of a current major depressive episode on the SCID
* Score of 17 or greater on the HDRS
* Failure to respond to two previous medication trials
* Capable of giving voluntary written consent

Exclusion Criteria:

* Hypersensitivity to penicillin or cephalosporin, resulting in anaphylaxis
* Significant current substance dependence/abuse within 3 months preceding the trial
* Significant history of intravenous drug abuse
* Active suicidal ideation
* Pregnant/lactating mothers
* Significant medical history
* Patients on anticoagulation treatment
* Patients who test positive for HIV or Hep B or C

Primary outcomes:
measure: Change in Hamilton Depression Rating Scale (HDRS) Score From Baseline.
timeFrame: 4 weeks
Secondary outcomes:
measure: Change in Score on the 16-item Quick Inventory of Depressive Symptoms (QIDS) From Baseline.
timeFrame: 4 weeks
measure: Number of Subjects Who Achieve Remission as Defined by a HDRS Score < 7.
timeFrame: 4 weeks
measure: Change in Montgomery Asberg Depression Rating Scale (MADRS)Score From Baseline.
timeFrame: 4 weeks
measure: Change in Ratings on the Clinical Global Impressions Scale for Bipolar Disorder (CGI-BP).
timeFrame: 4 weeks
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale University School of Medicine
state: Connecticut
Study officials:
affiliation: Yale University
name: Zubin Bhagwagar, MD PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Yale University
name: Gerard Sanacora, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mineur YS, Picciotto MR, Sanacora G. Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biol Psychiatry. 2007 Jan 15;61(2):250-2. doi: 10.1016/j.biopsych.2006.04.037. Epub 2006 Jul 24.
citation: Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005 Jan 6;433(7021):73-7. doi: 10.1038/nature03180.
Clinical trial NCT00659711: The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects
Official title: The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type 2 Diabetes
Lead sponsor: University at Buffalo
Sponsor class: OTHER
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2008-04-16
Enrollment: 22
Sex: ALL
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Sitagliptin is a new oral hypoglycemic anti-diabetic drug used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. Sitagliptin has been shown to have fewer side effects in the control of blood glucose values.

Obesity and diabetes are states of increased inflammation and can influence the free radicals and inflammatory markers (chemicals in the blood which increase due to inflammation in the body) and are also major risk factors for atherosclerotic disease. In this study we want to see the effect of sitagliptin on these markers. We believe that Sitagliptin may exert an anti-inflammatory effect in the human. The purpose of this study is to determine if the addition of sitagliptin to diabetic patients will provide added benefit. We believe that sitagliptin provides these added benefits by suppressing free radicals (charged substances that cause damage to the body) and inflammation.


Eligibility criteria: Inclusion Criteria:

* Males or females with age 20-75 years inclusive.
* Type 2 diabetes
* Males and Females BMI \> 30
* Subjects on statins, ACE inhibitors, thiazolidenediones and antioxidants will be allowed as long as they are on stable doses of these compounds and the dosage in not changed during the course of study.
* BP under control -No change required to BP medications
* HbA1c \> 7%

Exclusion Criteria:

* Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks
* Pregnancy
* Hepatic disease (abnormal LFT's),Renal impairment (serum creatinine \> 1.5),
* Participation in any other concurrent clinical trial
* Any other life-threatening, non-cardiac disease,
* Uncontrolled hypertension (BP \> 160/100 mm of Hg)
* Congestive Heart Failure
* Use of an investigational agent or therapeutic regimen within 30 days of study
* Subjects on Exenatide, incretin or insulin therapy

Primary outcomes:
measure: Change in Reactive Oxygen Species (ROS) Generation by MNC, Protein and mRNA Expression of p47phox Subunit of NADPH Oxidase, in MNC's of Obese Type 2 Diabetic Patients
timeFrame: 12 weeks
Secondary outcomes:
measure: Change in Oxidative Stress From Baseline to 12 Weeks
timeFrame: value at 12 weeks minus value at baseline
Other outcomes:
Locations:
city: Buffalo
country: United States
facility: 115 Flint Road
state: New York
Study officials:
affiliation: Kaleida Health
name: Paresh Dandona, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06953011: The Effects of Different Types of Music on Patients Undergoing Thyroid Surgery
Official title: The Effect of Preferred Music on Anxiety and Comfort Levels in Thyroidectomy Surgery: A Randomized Controlled Trial (RCT)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Thyroid
Keywords: Anxiety
Thyroidectomy
Music
Patient comfort
Lead sponsor: Dicle University
Sponsor class: OTHER
First posted: 2025-05-01
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Two groups with a conventional therapy control group
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study was conducted to investigate the effect preoperative music interventions on anxiety and postoperative comfort level in patients.

Detailed description: Objective: This study was conducted to investigate the effect of preoperative music interventions on anxiety and postoperative comfort levels in patients.

Design: A randomized controlled quasi-experimental design was used. Methods: This study was conducted in the general surgery clinic of a university hospital in Diyarbakır, Turkey. A total of 100 patients (47 in the intervention and 53 in the control group) participated in the study by randomization. Personal Information Form, hemodynamic parameters, and State-Trait Anxiety Inventory were used for data collection. The State part of the State-Trait Anxiety Inventory was re-administered to the intervention group after the music intervention. In the postoperative period, hemodynamic parameters of all patients in both groups were monitoredş and the Perianesthesia Comfort Questionnaire was administered. SPSS 25.0 software was used for data analysis.

Eligibility criteria: Inclusion Criteria:

* Ages of 18-65,
* Hospitalized for 24 hours after surgery,
* without cognitive impairment
* consenting to participate

Exclusion Criteria:

* Individuals under the age of 18 and over the age of 65
* Individuals with cognitive impairment
* Individuals who declined to participate in the study

Primary outcomes:
measure: State-Trait Anxiety Scale
timeFrame: six months
Secondary outcomes:
measure: Perianesthesia Comfort Questionnaire (PCQ)
timeFrame: six months
Other outcomes:
Locations:
city: Diyarbakir
country: Turkey
facility: Dicle University Hospital General Surgery Clinic
state: Sur
Study officials:
References:
Clinical trial NCT02735811: OBSERVational Registry on Long-term Outcome of ICD Patients
Official title: The Italian Multicentric OBSERVational Registry on Long-term Outcome of ICD Patients (OBSERVO-ICD Registry)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cardiomyopathies
Keywords: Implantable defibrillator
Cardiomyopathies
Lead sponsor: Azienda Ospedaliera Cardinale G. Panico
Sponsor class: OTHER
First posted: 2016-04-13
Enrollment: 1300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Consecutive patients underwent ICD implantation from January 2010 to December 2012 for any indication at enrolling hospitals

Brief summary: Multicentric, observational, retrospective registry including patients underwent ICD implantation for any indication. The primary aim of the registry is to evaluate the long-term outcome of patients receiving an ICD.

Detailed description: Multicentric, observational, retrospective registry including patients underwent ICD implantation for any indication in the period from 2010 to 2012. The aims of the registry are to evaluate the occurrence of complications related to ICD implantation (including ICD shocks and electrical storm), and the mortality during a long-term follow-up.

Eligibility criteria: Inclusion Criteria:

* ICD implantation fo any indication;
* age \>18 years

Exclusion Criteria:

* life expectancy of less than one year

Primary outcomes:
measure: Death for any cause
timeFrame: an average of 2 years
Secondary outcomes:
measure: Complications related to ICD implantation
timeFrame: an average of 2 years
Other outcomes:
Locations:
city: Tricase
country: Italy
facility: "Card. G. Panico" Hospital
state: Lecce
city: Ancona
country: Italy
facility: University Hospital "Umberto I - Lancisi - Salesi"
city: Bologna
country: Italy
facility: Policlinico S.Orsola-Malpighi
city: Catanzaro
country: Italy
facility: AO Pugliese-Ciaccio
city: Novara
country: Italy
facility: Ospedale Maggiore della Carità
city: Roma
country: Italy
facility: Ospedale San Filippo Neri
Study officials:
affiliation: Cardiology Unit - "Card. G. Panico" Hospital - Tricase
name: Pietro Palmisano, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Guerra F, Palmisano P, Dell'Era G, Ziacchi M, Ammendola E, Bonelli P, Patani F, Cupido C, Devecchi C, Accogli M, Occhetta E, Santangelo L, Biffi M, Boriani G, Capucci A; Italian Association of Arrhythmology and Cardiac Pacing (AIAC). Implantable cardioverter-defibrillator programming and electrical storm: Results of the OBSERVational registry On long-term outcome of ICD patients (OBSERVO-ICD). Heart Rhythm. 2016 Oct;13(10):1987-92. doi: 10.1016/j.hrthm.2016.06.007. Epub 2016 Jun 9.
Clinical trial NCT01418911: Attachment Style of Type 2 Diabetics, and Cognitive, Social and Emotional Variables as Explanatory Factors of Adherence to Self-care Behavior and Diabetes Control
Official title: Attachment Style of Type 2 Diabetics, and Cognitive, Social and Emotional Variables as Explanatory Factors of Adherence to Self-care Behavior and Diabetes Control
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Type 2 Diabetes Patients
Lead sponsor: Assuta Hospital Systems
Sponsor class: OTHER
First posted: 2011-08-17
Enrollment: 300
Sex: ALL
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Sampling method: NON_PROBABILITY_SAMPLE
Study population: type 2 diabetes 40-70 years of age Hebrew speaking members of maccabi healthcare services

Brief summary: This study will expand the understanding of factors associated with adherence to self care and the diabetes control among diabetes type 2 patients. The theoretical framework of the study incorporates central variables from two theoretical models: a cognitive model of health behavior - "Health Belief Model", and the Stress and Coping model. The study is innovative in its focus on the association between the patient's attachment style and adherence to self care and diabetes control, a topic less studied among diabetes patients, in addition to cognitive, social and emotional variables. Further emphasis is upon a comparison of the study model between males and females.


Eligibility criteria: Inclusion Criteria:

* type 2 diabetes
* 40-70 years of age
* Hebrew speaking
* members of maccabi healthcare services

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
facility: Maccabi Healthcare Services
Study officials:
References:
Clinical trial NCT06992011: A Randomized Controlled Trial Comparing Clinical Effectiveness of SMILE Versus SMILE Xtra in Myopia
Official title: A Randomized Controlled Trial Comparing Clinical Effectiveness of SMILE Versus SMILE Xtra in Myopia
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Myopia
Lead sponsor: Shanghai Zhongshan Hospital
Sponsor class: OTHER
First posted: 2025-05-28
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate and compare the clinical efficacy, biomechanical stability, and optical quality of SMILE and SMILE Xtra procedures in patients with myopia through a randomized controlled trial


Eligibility criteria: Inclusion Criteria:

1. Age 18-50 years
2. MRSE (Manifest Refraction Spherical Equivalent) -6.00D to -10.00D with refractive changes within ±0.50D in past 2 years
3. CDVA (Corrected Distance Visual Acuity) ≥ 20/25
4. Myopia progression ≤ 0.50D/year for ≥2 years
5. RST (Residual Stromal Thickness) ≥ 250μm after lenticule removal
6. Contact lens discontinuation as per protocol

Exclusion Criteria:

1. Other eye diseases (keratoconus, glaucoma, etc.)
2. Corneal scarring, cataracts affecting observation
3. Systemic diseases affecting surgery compliance
4. Prior ocular surgeries
5. Pregnancy, breastfeeding, or menstruation
6. Drug allergies to surgical medication

Primary outcomes:
measure: visual acuity
timeFrame: 1 week, 1 month,3 months， 6 months, 12 months, 24 months, and 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Zhongshan Hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT06956911: Effect of Early Low Resisted Exercise With Blood Flow Restriction on Pulmonary Function in Post Cardiac Surgery Patient
Official title: Effect of Early Low Resisted Exercise With Blood Flow Restriction on Pulmonary Function in Post Cardiac Surgery Patient
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Coronary Artery Bypass Grafting
Post Coronary Artery Bypass Grafting
Keywords: Post Coronary Artery Bypass Grafting
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2025-05-04
Enrollment: 50
Sex: MALE
Minimum age (years): 45
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: After cardiac surgery Patients present a loss of exercise capacity, muscle mass, and quality of life Cardiopulmonary rehabilitation aims to reduce the loss of muscle strength, size and increase cardiopulmonary function so that quality of life is maintained as much as possible after open-heart surgeries. Traditionally, cardiac rehabilitation consist of low-intensity aerobic exercise. Therefore, cardiac rehabilitation should include not only aerobic but also resistance training (RT),. A safe and effective version of RT is needed that can still improve muscle strength and size in patients early after cardiac surgery,It is found that BFR can achieve the same result with low intensity which is suitable for patient post cardiac surgery,so the result of this study will provide a safe resisted exercise useful for post cardiac surgery patient


Eligibility criteria: Inclusion Criteria:

* Male patient aged from 45-60
* Elective open heart surgery via median sternotomy
* Post operative, extubated post open heart surgery, who can follow the instructions and sign the consent form
* Hemodynamic stability
* Neurological stability

Exclusion Criteria:

* Still on mechanical ventilation more than 48 hours
* Neuromuscular diseases
* Rheumatoid arthritis
* Coagulopathy
* Chronic Obstructive Pulmonary Disease (COPD)
* Cardiac arrhythmias

Primary outcomes:
measure: pulmonary function test, parameters that be measured is FVC and will be expressed as % of the predicted value for age,height,weight and sex and FEV1 and will be expressed as % of the predicted value of age ,sex,weight and height
timeFrame: fourteen days
measure: Hand grip strength
timeFrame: fourteen days
measure: c-reactive protein lab
timeFrame: fourteen days
measure: Functional capacity
timeFrame: fourteen days ,first measure will be at the session of assessment and last measure will be at the end of treatment program after fourteen days
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: National heart institute
Study officials:
References:
Clinical trial NCT00035711: VA HDL Intervention Trial (VA-HIT) Ancillary Study Data Analysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Disease
Heart Diseases
Cardiovascular Diseases
Carotid Artery Diseases
Diabetes Mellitus, Non-insulin Dependent
Hypertension
Insulin Resistance
Obesity
Diabetes Mellitus
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Sponsor class: NIH
First posted: 2002-05-06
Sex: MALE
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE

Brief summary: To evaluate additional cardiovascular risk factors using data from the VA HDL Intervention Trial (VA-HIT).

Detailed description: BACKGROUND:

The VA HDL Intervention trial (VA-HIT) was a multicenter, placebo controlled, randomized trial that showed that gemfibrozil significantly reduced major cardiovascular events in 2531 men with coronary heart disease, low levels of low density lipoprotein (LDL) cholesterol and low levels of high density lipoprotein (HDL) cholesterol. In addition to its unique lipid profile, the VA-HIT population also had a high prevalence of diabetes, impaired fasting glucose, or high fasting plasma insulin; central obesity; and hypertension, which are all components (together with high triglycerides and low HDL-cholesterol) of a constellation of risk factors known as the metabolic syndrome. Since prior clinical trials have not enrolled this type of population, the VA- HIT database is a unique resource.

DESIGN NARRATIVE:

The study used the VA-HIT database to study additional risk markers that were measured in the study population of 2,531 men with coronary heart disease. Specific analyses were: 1) the association between levels of glucose tolerance, insulin resistance and other features of the metabolic syndrome, occurrence of major cardiovascular outcomes, and gemfibrozil efficacy; 2) the effect of gemfibrozil on progression of carotid atherosclerosis, as measured by B-mode ultrasound; 3) the association between LDL particle size distribution and lipoprotein subclass distribution; homocysteine; lipoprotein(a); C-reactive protein, tissue plasminogen activator; fibrinogen; and factor VII; major cardiovascular outcomes and gemfibrozil efficacy.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

Eligibility criteria: No eligibility criteria

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: VA Medical Center
name: Hanna Rubins
References:
Clinical trial NCT01655511: Safety And Pharmacokinetic Assessment Of Orally Administered Tafamidis In Healthy Volunteers
Official title: A Phase 1, Randomized, Double-Blind, Crossover, Ascending Dose-Tolerance Study To Assess The Safety And Pharmacokinetics Of Tafamidis Doses Greater Than 120 Mg As Oral Solution In Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: TTR Cardiomyopathy
Keywords: Pharmacokinetic
pharmacodynamic
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2012-08-02
Enrollment: 9
Sex: ALL
Minimum age (years): 21
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: This study in healthy male and female volunteers will investigate the safety and tolerability of three increasing oral doses of tafamidis


Eligibility criteria: Inclusion Criteria:

* Healthy, males or females, 21 to 55 years old.
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2.

Exclusion Criteria:

Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).

Condition affecting drug absorption. Blood pressure or ECG abnormalities. Recent treatment with an investigational, prescription, or non-prescription drug

Primary outcomes:
measure: To evaluate the safety and tolerability of orally administered tafamidis in healthy volunteers at escalating doses >120 mg. Safety assessments will include spontaneous reporting of adverse events, concomitant medications, physical examination,
timeFrame: Day 0 and Day 6
measure: vital signs, ECGs, and clinical laboratory tests.
timeFrame: Day 0 and Day 6
Secondary outcomes:
measure: Cmax - Maximum Observed Plasma Concentration (Cmax)
timeFrame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs
measure: tmax - Time to Reach Maximum Observed Plasma Concentration (Tmax)
timeFrame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs
measure: AUC0-24 - AreArea under the Concentration-Time Curve (AUC)
timeFrame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs
measure: AUClast - Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]
timeFrame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs
measure: AUCinf - Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]
timeFrame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs
measure: t½ - Plasma Decay Half-Life (t1/2)
timeFrame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs
measure: Transthyretin blood concentration in mg/dL
timeFrame: Days 0,1,2,3,4,5,6
measure: Transthyretin stabilization (%)
timeFrame: Days 0,1,2,3,4,5,6
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References: